Regeneron Pharmaceuticals (REGN) Accounts Payables (2009 - 2026)

Regeneron Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Accounts Payables rose 45.58% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 45.58% increase from a year earlier, with the FY2025 full-year figure at $939.0 million, up 18.94% from the prior year.
• Accounts Payables advanced to $1.0 billion in Q1 2026 per REGN's latest filing, from $939.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $1.0 billion in Q1 2026 and bottomed at $470.3 million in Q1 2022.
• The 5-year median for Accounts Payables is $599.5 million (2023), against an average of $661.1 million.
• Across the five-year window, Accounts Payables slipped 13.37% in 2022 and jumped 81.74% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $589.2 million in 2022, then climbed by 2.95% to $606.6 million in 2023, then jumped by 30.15% to $789.5 million in 2024, then climbed by 18.94% to $939.0 million in 2025, then rose by 9.38% to $1.0 billion in 2026.
• Per Business Quant, the three latest REGN Accounts Payables figures stand at $1.0 billion (Q1 2026), $939.0 million (Q4 2025), and $903.8 million (Q3 2025).